0.15Open0.17Pre Close143 Volume986 Open Interest9.50Strike Price1.88KTurnover288.44%IV11.18%PremiumDec 13, 2024Expiry Date0.00Intrinsic Value100Multiplier0DDays to Expiry0.05Extrinsic Value100Contract SizeAmericanOptions Type0.1358Delta0.2883Gamma171.80Leverage Ratio-0.2404Theta0.0000Rho23.33Eff Leverage0.0006Vega
Altimmune Stock Discussion
Altimmune Presents New Data on the Effect of Pemvidutide on Inflammatory Lipids in Subjects with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) at The Liver Meeting® 2024
Altimmune (Nasdaq: ALT) presented new data from its 12-week Phase 1b trial of pemvidutide in MASLD patients at The Liver Meeting®.
The study demonstrated that weekly subcutaneous doses of pemvidutide significantly reduced inflammatory lipids and showed promising effects on cardiovascul...
Larger Image: tradingview.com...
$Altimmune (ALT.US)$
Will a partner be announced or are the rumours true a buy out is eminent..!
Larger Image: tradingview.com...
$Altimmune (ALT.US)$
No comment yet